A groundbreaking blood test developed by Grail can identify 50 types of cancer at all stages, addressing the urgent need for early detection in cancers that currently lack screening options. With cancer claiming millions of lives annually, early intervention dramatically increases survival rates. The strategic acquisition of Grail by Illumina aims to expedite the test's availability worldwide, leveraging their extensive commercial presence and expertise in regulatory processes.
